{
    "root": "c49f1984-15f8-4922-bb8c-358b10e7130a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TOLTERODINE TARTRATE",
    "value": "20250507",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "OLEIC ACID",
            "code": "2UMI9U37CP"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TOLTERODINE TARTRATE",
            "code": "5T619TQR3R"
        }
    ],
    "indications": "tolterodine tartrate extended-release capsules antimuscarinic indicated treatment overactive bladder symptoms urge urinary incontinence , urgency , frequency . ( 1 )",
    "contraindications": "4 mg capsules taken orally daily water swallowed whole . ( 2.1 ) 2 mg capsules taken orally daily water swallowed whole presence : ° mild moderate hepatic impairment ( child-pugh class b ) ( 2.2 ) ° severe renal impairment [ creatinine clearance ( ccr ) 10 30 ml/min ] ( 2.2 ) ° drugs potent cyp3a4 inhibitors . ( 2.2 ) tolterodine tartrate extended-release capsules recommended patients ccr < 10 ml/min . ( 2.2 ) tolterodine tartrate extended-release capsules recommended patients severe hepatic impairment ( child-pugh class c ) . ( 2.2 )",
    "warningsAndPrecautions": "tolterodine tartrate extended-release capsules , usp supplied follows : 2 mg capsules size `` 4 `` , hard gelatin capsules green cap green body , imprinted `` 1189 `` cap white ink , containing off-white brownish colored pellets . bottles 30 ndc 13668-189-30 bottles 90 ndc 13668-189-90 bottles 500 ndc 13668-189-05 100 unit dose capsules ndc 13668-189-74 4 mg capsules size `` 3 `` , hard gelatin capsules blue cap blue body , imprinted `` 1190 `` cap white ink , containing off-white brownish colored pellets . bottles 30 ndc 13668-190-30 bottles 90 ndc 13668-190-90 bottles 500 ndc 13668-190-05 100 unit dose capsules ndc 13668-190-74 store tolterodine tartrate extended-release capsules , usp 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "tolterodine tartrate extended-release capsules contraindicated patients urinary retention , gastric retention , uncontrolled narrow-angle glaucoma . tolterodine tartrate extended-release capsules also contraindicated patients known hypersensitivity ingredients , fesoterodine fumarate extended-release tablets , like tolterodine tartrate extended-release capsules , metabolized 5-hydroxymethyl tolterodine . ( 4 )",
    "indications_original": "Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )",
    "contraindications_original": "4 mg capsules taken orally once daily with water and swallowed whole. ( 2.1 ) 2 mg capsules taken orally once daily with water and swallowed whole in the presence of: °  mild to moderate hepatic impairment (Child-Pugh class A or B)  ( 2.2 ) °  severe renal impairment [Creatinine Clearance (CCr) 10 to 30 mL/min] ( 2.2 ) °  drugs that are potent CYP3A4 inhibitors. ( 2.2 ) Tolterodine tartrate extended-release capsules are not recommended for use in patients with CCr <10 mL/min. ( 2.2 ) Tolterodine tartrate extended-release capsules are not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). ( 2.2 )",
    "warningsAndPrecautions_original": "Tolterodine tartrate extended-release capsules, USP are supplied as follows:\n                  2 mg capsules are size \"4\", hard gelatin capsules having a green cap and green body, imprinted \"1189\" on the cap with white ink, containing off-white to brownish colored pellets.\n                  Bottles of 30                           NDC 13668-189-30\n                  Bottles of 90                           NDC 13668-189-90\n                  Bottles of 500                         NDC 13668-189-05\n                  100 Unit dose capsules           NDC 13668-189-74\n                  4 mg capsules are size \"3\", hard gelatin capsules having a blue cap and blue body, imprinted \"1190\" on the cap with white ink, containing off-white to brownish colored pellets.\n                  Bottles of 30                           NDC 13668-190-30\n                  Bottles of 90                           NDC 13668-190-90\n                  Bottles of 500                         NDC 13668-190-05\n                  100 Unit dose capsules           NDC 13668-190-74\n                  Store tolterodine tartrate extended-release capsules, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine. ( 4 )"
}